Morgan Stanley: Pharmaron orders advance toward commercialization, with a breakthrough expected in 2027
New CDMO purchase orders rose 40% year on year in the third quarter of 2026, and the revenue share of late-stage and commercial projects is expected to rise; capacity expansion and delivery of large orders will affect the realization of growth and margins.